Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

In vitro pharmacological profile of the A2A receptor antagonist istradefylline.

Saki M, Yamada K, Koshimura E, Sasaki K, Kanda T.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Nov;386(11):963-72. doi: 10.1007/s00210-013-0897-5. Epub 2013 Jun 29.

PMID:
23812646
2.

The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

Eur J Pharmacol. 2015 Jan 15;747:160-5. doi: 10.1016/j.ejphar.2014.11.038. Epub 2014 Dec 11.

PMID:
25499739
3.

Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.

Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, Kanda T.

Psychopharmacology (Berl). 2014 Jul;231(14):2839-49. doi: 10.1007/s00213-014-3454-0. Epub 2014 Feb 2.

PMID:
24488405
4.

Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents.

Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T.

Pharmacol Biochem Behav. 2013 Dec;114-115:23-30. doi: 10.1016/j.pbb.2013.10.022. Epub 2013 Nov 4.

PMID:
24201052
5.

Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.

Kadowaki Horita T, Kobayashi M, Mori A, Jenner P, Kanda T.

Psychopharmacology (Berl). 2013 Dec;230(3):345-52. doi: 10.1007/s00213-013-3158-x. Epub 2013 Jun 10.

PMID:
23748382
6.

Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):133-44. Epub 2007 Feb 20.

PMID:
17310264
7.

JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.

Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, Drinkenburg WH, Ahnaou A, Te Riele P, Langlois X, Hrupka B, De Haes P, Hendrickx H, Aerts N, Hens K, Wellens A, Vermeire J, Megens AA.

ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19. doi: 10.1021/cn5001606. Epub 2014 Sep 24.

PMID:
25203719
8.

The safety of istradefylline for the treatment of Parkinson's disease.

Müller T.

Expert Opin Drug Saf. 2015 May;14(5):769-75. doi: 10.1517/14740338.2015.1014798. Epub 2015 Feb 13. Review.

PMID:
25676023
9.

The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.

Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

Eur J Pharmacol. 2015 Nov 5;766:25-30. doi: 10.1016/j.ejphar.2015.09.028. Epub 2015 Sep 28.

PMID:
26415982
10.

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.

Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y.

Psychopharmacology (Berl). 1999 Nov;147(1):90-5.

PMID:
10591873
11.

Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.

Müller T.

Expert Opin Drug Metab Toxicol. 2013 Aug;9(8):1015-24. doi: 10.1517/17425255.2013.795541. Epub 2013 May 6. Review.

PMID:
23642267
12.

Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.

Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T.

J Pharmacol Sci. 2014;124(4):480-5. Epub 2014 Mar 28.

14.

The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G, Coll MG.

Br J Pharmacol. 1995 Jul;115(6):1096-102.

15.

Istradefylline for the treatment of Parkinson's disease.

Park A, Stacy M.

Expert Opin Pharmacother. 2012 Jan;13(1):111-4. doi: 10.1517/14656566.2012.643869. Review.

PMID:
22149371
16.

The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.

Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S.

J Pharmacol Exp Ther. 1996 Feb;276(2):398-404.

PMID:
8632302
17.

KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist.

Nonaka H, Ichimura M, Takeda M, Nonaka Y, Shimada J, Suzuki F, Yamaguchi K, Kase H.

Eur J Pharmacol. 1994 May 17;267(3):335-41.

PMID:
8088373
18.

Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors.

Kull B, Ferré S, Arslan G, Svenningsson P, Fuxe K, Owman C, Fredholm BB.

Biochem Pharmacol. 1999 Sep 15;58(6):1035-45.

PMID:
10509756
19.
20.

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF.

Parkinsonism Relat Disord. 2009 Jul;15(6):406-13. doi: 10.1016/j.parkreldis.2008.12.006. Epub 2009 May 15. Review.

PMID:
19446490

Supplemental Content

Support Center